Marché mondial des modificateurs de pH urinaire – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché

Les médicaments utilisés pour traiter les problèmes des reins, de la vessie, des uretères et de l'urètre sont connus sous le nom de médicaments génito-urinaires . Les patients souffrant de maladies et d'infections du système génito-urinaire ont longtemps eu recours à des stéroïdes et des immunosuppresseurs fabriqués chimiquement, qui peuvent provoquer des effets secondaires majeurs tels que l'insomnie, l'acné, les nausées, les vomissements et la diarrhée. Par conséquent, les patients se tournent de plus en plus vers des médicaments biologiques, qui ont moins ou pas d'effets indésirables et sont plus efficaces pour traiter les infections génito-urinaires. Le pH urinaire peut induire ou aggraver certaines maladies, dont la plus courante est la lithiase urinaire. L'utilisation de médicaments qui modifient le pH urinaire est fréquemment recommandée dans le traitement et la prévention de ces troubles.

Français Data Bridge Market Research analyse que le marché des modificateurs de pH urinaire était évalué à 2,2442 milliards USD en 2021 et devrait atteindre 3,02 milliards USD d'ici 2029, enregistrant un TCAC de 3,80 % au cours de la période de prévision de 2022 à 2029. En plus des informations sur le marché telles que la valeur du marché, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée du rapport et segmentation du marché

Market Definition

Urinary pH modifiers are substances that raise urine's pH. They make urine more alkaline, which helps to prevent kidney stones. Making urine more alkaline aids the kidneys in the removal of toxins. The various types of urinary pH modifiers employed in the treatment of genitourinary disorders include potassium acid phosphate, sodium bicarbonate, sodium citrate, and potassium citrate.

Urinary pH Modifiers Market Dynamics

Drivers

• Increasing prevalence of renal failure

The rising prevalence of renal failure is anticipated to influence the urinary pH modifiers? market's growth. Kidney stones are a prevalent condition, with an annual incidence of eight cases per 1,000 people, according to Leonardo Ferreira of the American Academy of Family Physicians (AAFP) in March 2020. According to the same source, around 13% of men and 7% of women will develop a kidney stone over their lifetime, with a total incidence of urinary retention in the United States ranging from 4.5 to 6.8% per 1,000 males.

• Rising prevalence of diabetes

The increasing prevalence of diabetes is expected to flourish the market’s growth rate during the forecast period of 2022-2029. Patients with diabetes are particularly vulnerable to urinary tract infections. Due to the narrow length of the urethra, which allows bacteria to enter more easily, women are more susceptible to this disease. According to the International Diabetes Federation, the global prevalence of diabetes is expected to rise to 552 million by 2030, up from 366 million in 2011. The rising prevalence of diabetes is expected to increase demand for genitourinary medications in the coming years. Urinary Tract Infections (UTIs) infect more than 150 million individuals worldwide each year, costing the healthcare system about USD 6 billion in direct costs. Bladder cancer affects approximately 2.4 percent of women and men at some point in their lives.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the urinary pH modifiers? market. Additionally, rising level of governmental funding towards healthcare and surging level of disposable income will result in the expansion of urinary pH modifiers? market. Along with this, rising frequency of cancer and increasing geriatric population will enhance the growth rate of the market.

Opportunities

• Increase in the number of product launches

During the forecast timeline, the industry is expected to thrive due to an increase in the number of product launches. For instance, the FDA approved cefiderocol (FETROJA) in November 2019 for complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative microorganisms such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Pseudomonas aeruginosa, and Entero. This will provide beneficial opportunities for the urinary pH modifiers? market growth.

• Rising number of mergers and acquisitions

The market is expected to rise in the next years as the number of mergers and acquisitions increases. For illustration, AbbVie Inc. agreed to pay USD 63 billion for competitor manufacturer, Allergan Plc in June 2019, the latest acquisition in an industry where some of the top businesses have been willing to pay a high premium to answer doubts about their future prospects. Due to the merger of these two firms, the product line comprising of pharmaceuticals for the treatment of genitourinary illnesses would gain a larger distribution channel, which will benefit market growth throughout the forecast period.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the urinary pH modifiers? market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with drug development and distribution will obstruct the market’s growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the urinary pH modifiers? market. Additionally, surging number of counterfeit drugs and lack of awareness among people about the infection as well as drugs will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This urinary pH modifiers? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the urinary pH modifiers? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Urinary pH modifiers? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Urinary pH Modifiers Market

The unusual rise in coronavirus-infected patients hampered access to other primary care services and led in a large decline in diagnoses other than COVID-19, such as genitourinary tract infection. Coronaviruses can induce urological symptoms when they infect the genitourinary system, according to a research published in the Asian Journal of Urology in July 2021. COVID-19 is the cause of genitourinary organ damage and dysfunction. Several investigations have discovered that COVID-19 patients had kidney damage. Furthermore, COVID-19 infection poses the greatest harm to the respiratory, digestive, and reproductive systems, as per a study released in the International Journal of Environmental Research and Public Health in April 2020.  COVID-19 has a considerable impact on the genitourinary market. However, as a consequence of high demand for COVID-19 vaccines and treatment medications, the pharmaceutical and biotechnology industries are expected to increase significantly in the next years.

Global Urinary pH Modifiers Market Scope

The urinary pH modifiers? market is segmented on the basis of drug, indication, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Alkalosis
• Alkylating Agent Cystitis
• Asystole
• Gastroesophageal reflux disease (GERD)
• Diabetic Ketoacidosis
• Hyperkalemia
• Hyponatremia
• Indigestion
• Metabolic Acidosis
• Nephrolithiasis
• Urinary Acidification
• Urinary Alkalinization
• Others

Drug

• Potassium Acid Phosphate
• Sodium Bicarbonate
• Sodium Citrate
• Potassium Citrate

Dosage

• Injection
• Tablets
• Solution
• Powder
• Others

Route of Administration

• Intravenous
• Extracorporeal
• Oral
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Urinary pH Modifiers Market Regional Analysis/Insights

The urinary pH modifiers? market is analyzed and market size insights and trends are provided by country, drug, indication, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the urinary pH modifiers? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the urinary pH modifiers? market because of the increasing prevalence of major genitourinary diseases in this region. Additionally, growing presence of major key players and well-established healthcare infrastructure will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to rising level of disposable income and improvements in healthcare infrastructure in this region. Also, rapid high R&D investment deployed by the global players will further propel the market’s growth rate in this region.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché des modificateurs du pH urinaire

Le paysage concurrentiel du marché des modificateurs de pH urinaires fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des modificateurs de pH urinaires.

Certains des principaux acteurs opérant sur le marché des modificateurs de pH urinaire sont :

• Sanofi (France)
• Novartis SA (Suisse)
• Teva Pharmaceutical Industries Ltd. (Irlande)
• Pfizer Inc. (États-Unis)
• GlaxoSmithKline plc (Royaume-Uni)
• Johnson & Johnson Private Limited (États-Unis)
• Eli Lilly and Company (États-Unis)
• Abbott (États-Unis)
• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Melinta Therapeutics LLC (États-Unis)
• Merck & Co., Inc. (États-Unis)
• AstraZeneca (Royaume-Uni)
• Ionis Pharmaceuticals (États-Unis)
• Genentech Inc. (États-Unis)
• Société Bristol-Myers Squibb (États-Unis)
• Allergan (Irlande)
• Cipla Inc. (États-Unis)
• Astellas Pharma Inc. (Japon)
• Bayer AG (Allemagne)

SKU-68379